by
Thomas Dworetzky, Contributing Reporter | October 12, 2015
“[The Nestlé facility] is really going to make it an area for innovation,” she said. “It’s a great New Jersey story and it shows that we are able to reinvent ourselves in a space that was huge, and now we’ve been able to develop it in a way — working together with [owners Advance Realty and CrossHarbor Capital Partners] — to make it a destination for life sciences.”
Nestlé Health Sciences has been in the news recently with a number of other deals. In September it entered into a deal for exclusive rights to Lipid Therapeutics' LT-02 compound (phosphatidylcholine), a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis (UC), worldwide excluding Europe and Australia.
Ad Statistics
Times Displayed: 19563
Times Visited: 365 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
In addition, The Nestlé Institute of Health Sciences SA signed a research collaboration agreement in September with AC Immune SA to develop a sensitive, minimally invasive Tau diagnostic assay for early Alzheimer's disease using Nestlé's proprietary multiplexed ultrasensitive antibody technology platform.
Back to HCB News
